• About Us
  • Corporate Profile
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Respiratory and Acute Care Advisory Board
  • Cardiovascular Advisory Board
  • Immunology Advisory Board
  • Investors
• Products
• Research
  • sPLA2 - What is it?
  • Respiratory and Acute Care Program
  • sPLA2 in SCD
  • IMPACTS Trial Site
  • Scientific Advisory Board
  • Cardiovascular Program
  • sPLA2 in CVD
  • FRANCIS Trial Site
  • PLASMA Trial Site
  • PLASMA 2 Trial Site
  • Scientific Advisory Board
  • Immunology Program
  • A-623 in SLE and Autoimmune Diseases
  • Scientific Advisory Board
  • Preclinical Programs
  • Glossary
  • References
• News & Media
• Careers
• Contact Us

<< Return to Scientific Advisory Board

Scientific Advisory Board: Cardiovascular

Robert S. Rosenson‚ MD‚ FACC‚ FACP‚ FAHA

Dr. Robert Rosenson is Professor of Medicine and Director of Lipoprotein Disorders and Clinical Atherosclerosis Research / Cardiovascular Diseases at the University of Michigan in Ann Arbor. His clinical research has investigated the effects of lipid-lowering therapies‚ hypoglycemic therapies and antihypertensive agents on inflammation and thrombogenesis as well as the effects of hyplolipidemic and antihypertensive agents on blood viscosity and fibrinogen. Previously‚ he was Professor of Cardiology at Northwestern University Medical School‚ where he also served as Director of the Preventative Cardiology Center and Director of the Lipoprotein and Hemorheology Research Facility. After receiving his medical degree from Tulane University‚ Dr. Rosenson completed his internship and residency at Brigham and Women’s Hospital‚ Harvard Medical School‚ where he also held a Clinical Fellowship in Medicine. Following that‚ Dr. Rosenson completed his fellowship in cardiology at the University of Chicago. He has published over 70 peer-reviewed scientific papers and nearly 70 book chapters in the field. He also serves as an editor of a number of journals including Atherosclerosis.